Succinylcholine Chloride is a drug owned by Hikma Pharmaceuticals Usa Inc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 02, 2041. Details of Succinylcholine Chloride's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12295932 | Succinylcholine chloride prefilled syringe |
Nov, 2041
(15 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Succinylcholine Chloride's patents.
Latest Legal Activities on Succinylcholine Chloride's Patents
Given below is the list of recent legal activities going on the following patents of Succinylcholine Chloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 20 May, 2025 | US12295932 |
| Email Notification | 13 May, 2025 | US12295932 |
| Patent Issue Date Used in PTA Calculation | 13 May, 2025 | US12295932 |
| Recordation of Patent eGrant | 13 May, 2025 | US12295932 |
| Patent eGrant Notification | 13 May, 2025 | US12295932 |
| Mail Patent eGrant Notification | 13 May, 2025 | US12295932 |
| Email Notification | 01 May, 2025 | US12295932 |
| Issue Notification Mailed | 30 Apr, 2025 | US12295932 |
| Application Is Considered Ready for Issue | 15 Apr, 2025 | US12295932 |
| Dispatch to FDC | 15 Apr, 2025 | US12295932 |
US patents provide insights into the exclusivity only within the United States, but
Succinylcholine Chloride is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Succinylcholine Chloride's family patents as well as insights into
ongoing legal events
on those patents.
Succinylcholine Chloride's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Succinylcholine Chloride's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 02, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Succinylcholine Chloride Generic API suppliers:
Succinylcholine Chloride is the generic name for the brand Succinylcholine Chloride. 26 different companies have already filed for the generic of Succinylcholine Chloride, with Fresenius Kabi Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Succinylcholine Chloride's generic
About Succinylcholine Chloride
Succinylcholine Chloride is a drug owned by Hikma Pharmaceuticals Usa Inc. Succinylcholine Chloride uses Succinylcholine Chloride as an active ingredient. Succinylcholine Chloride was launched by Hikma in 2021.
Approval Date:
Succinylcholine Chloride was approved by FDA for market use on 20 August, 2021.
Active Ingredient:
Succinylcholine Chloride uses Succinylcholine Chloride as the active ingredient. Check out other Drugs and Companies using Succinylcholine Chloride ingredient
Dosage:
Succinylcholine Chloride is available in solution form for intramuscular, intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG/5ML (20MG/ML) | SOLUTION | Prescription | INTRAMUSCULAR, INTRAVENOUS |